Coagulation parameters in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis during and after dose reduction of biologicals

Coagulation parameters in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis during and after dose reduction of biologicals - Effects of dose reduction of biologicals on coagulation

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON43241

Enrollment

300

Registered

2016-06-08

Start date

2016-07-01

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

auto-inflammatory joint diseases Rheumatism

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Diagnosis RA, AS or PsA Use of biologicals Reducing biological due to low disease activity (to be determined by the treating rheumatologist)

Exclusion criteria

Exclusion criteria: Insufficient understanding of the Dutch language to be able to sign informed consent

Design outcomes

Primary

Measure	Time frame
Additional blood samples will be taken during three consecutive visits to the 'biopoli'. These will be stored at a temperature of -80 ° C. The following biomarkers of coagulation activation will be determined: F1 + 2, prothrombin fragments1 and 2 TAT, thrombin-antithrombin complexes PAP, plasmin-a2-antiplasmin inhibitor complex TGA, trombin generation analysis	—

Secondary

Measure	Time frame
Not applicable.	—

Countries

Netherlands

Outcome results